Mode
Text Size
Log in / Sign up
Phase 1 N=18 Treatment

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Healthy Adult Male

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 — 47.4; 44.9; 46.1 ng/mL

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
OPC-34712 (Drug)
Age
Adult · 20+ yrs
Sex
Male
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Primary completion
Nov 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Plasma Concentration (Cmax) of OPC-34712
47.4; 44.9; 46.1
PRIMARY
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712
2920; 2830; 2770

Summary

The ratios of the geometric means of the ODT formulation to those of the reference formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of brexpiprazole (OPC-34712)).

Eligibility Criteria

Inclusion Criteria

  • Capable of providing written informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all requirements of the trial

Exclusion Criteria

  • Clinically significant abnormality at the time of screening (eg, significant deviation from reference ranges) or in medical history that, in the opinion of investigator or sponsor may place the subject at risk or interfere with outcome variables, including drug absorption, distribution, metabolism, and excretion
  • History of serious mental disorder
  • History of drug or alcohol abuse within 2 years prior to screening
  • History of any significant drug allergy
  • Use of an investigational drug within 120 days prior to the first dosing of trial drug
  • Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to screening
  • Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange products, starfruit, or starfruit products within 72 hours prior to dosing
  • Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or St. John's Wort within 14 days prior to the first dosing of trial drug, or of antibiotics within 30 days prior to the first dosing of trial drug
  • History of major surgery of the digestive tract (excluding appendectomy)
  • Any subject who, in the opinion of the investigator, should not participate in the trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02875080). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search